Category: Finance
-
Clinical-Stage Biotech Lands $15M in Early Venture Funding
4 June 2014. Trevi Therapeutics Inc., a biotechnology company in New Haven, Connecticut developing therapies for chronic itching conditions, secured $15 million in its second venture financing round. The funding, the first installment in a projected $25 million round, was led by current investor TPG Biotech and includes current angel investors in the company. Trevi…
-
Project Underway to Enable Mobile Health Data Collection
3 June 2014. A joint project of the University of California campuses in San Diego and Irvine aims to answer technical and policy questions needed to collect health-related data from mobile devices and social networks for public health research. The Health Data Exploration Network project received a $1.9 million grant from the Robert Wood Johnson…
-
Challenge Seeks Methods to More Accurately Detect Epilepsy
2 June 2014. Mayo Clinic in Rochester, Minnesota and University of Pennsylvania in Philadelphia are seeking through an open competition new techniques to detect epilepsy seizures sooner and more accurately. The Seizure Detection Challenge has a total prize purse of $8,000 and a deadline for submissions of 19 August 2014. Epilepsy is a neurological disorder…
-
Epigenetics Biotech Secures $12.9 Million Early Financing
30 May 2014. Rodin Therapeutics Inc., a biotechnology company in Boston developing therapies based on epigenetics — inherited changes in genetic activity outside of DNA — raised $12.9 million in its first venture funding round. The company is a joint venture of Proteros biostructures GmbH in Munich and Atlas Ventures in Cambridge, Massachusetts. Rodin Therapeutics…
-
Remote Heart Failure Monitoring Device Approved by FDA
29 May 2014. The U.S. Food and Drug Administration yesterday approved an implanted device that measures pulmonary artery pressure and heart rate of patients with moderate heart failure who were hospitalized in the previous year. The device, the CardioMEMS HF System, is made by CardioMEMS Inc. in Atlanta. St. Jude Medical, a medical device manufacturer…
-
Medical Centers to Develop Brain Signal Tracking, Therapies
28 May 2014. Massachusetts General Hospital in Boston and University of California in San Francisco are developing technologies to analyze brain activity and deliver near real-time neural stimulation therapies. The five-year project is funded by grants from Defense Advanced Research Projects Agency (DARPA) of $30 million and $26 million respectively to Mass. General and UC-San…
-
Antibody Developer Secures $40M from Foundation Investors
16 May 2014. Kymab Ltd., a developer of human antibodies from mouse genomes, raised $40 million in its second round of venture investment from the Wellcome Trust, an original backer of the company, and Bill & Melinda Gates Foundation. Kymab, based in Cambridge, U.K., is also collaborating with the Gates Foundation in research on discovery…
-
Neurodegenerative Therapies Start-Up Gains $4.8M Seed Funds
12 May 2014. Lysosomal Therapeutics Inc., a start-up developer of therapies for neurodegenerative disorders in Cambridge, Massachusetts, raised $4.8 million in seed financing, the enterprise’s initial operating funds. The company was begun by and is based on the research of Dimitri Krainc, a neurologist at Harvard Medical School and Massachusetts General Hospital in Boston. Atlas…
-
Biopharm, University Partner on Universal Flu Vaccine
8 May 2014. Etubics Corp. in Seattle and University of Texas Medical Branch in Galveston are developing a new type of flu vaccine that aims to provide continuous protection against a variety of seasonal virus strains. The five-year project is funded by a $4.4 million grant from National Institute of Allergy and Infectious Diseases (NIAID),…
-
Biotech Alliance to Humanize Pig Lungs for Transplant
7 May 2014. Synthetic Genomics Inc. in La Jolla, California and Lung Biotechnology Inc. in Silver Spring, Maryland are developing synthetic lungs from pigs for patients with end-stage lung diseases needing a transplant. While all financial aspects of the deal were not disclosed, United Therapeutics Corporation — the parent company of Lung Biotechnology — is…